تأثیر ویتامین D بر مقاومت به انسولین در بیماران دیابتی نوع دو: مدل هم‌گروهی جامع

نوع مقاله : مقاله های پژوهشی

نویسندگان

1 دانشجوی کارشناسی ارشد، گروه اپیدمیولوژی و آمارزیستی، دانشکده‌ی بهداشت و کمیته‌ی تحقیقات دانشجویی، دانشگاه علوم پزشکی اصفهان، اصفهان، ایران

2 دانشیار، گروه اپیدمیولوژی و آمارزیستی، دانشکده‌ی بهداشت، دانشگاه علوم پزشکی اصفهان، اصفهان، ایران

3 استادیار، مرکز توسعه‌ی تحقیقات بالینی، دانشگاه علوم پزشکی قم، قم، ایران

چکیده

مقدمه: شماری از مطالعات مشاهده‌ای نشان داده‌اند که مصرف ویتامینD یکی از اقدامات پیشگیرانه‌ای است که نقش بالقوه‌ای در کاهش پیشرفت دیابت نوع 2، مقاومت به انسولین و سندرم متابولیک دارد. هدف این مطالعه، بررسی تأثیر ویتامین D بر مقاومت به انسولین در بیماران مبتلا به دیابت نوع دو در شهر قم بود.روش‌ها: مطالعه در قالب مدل هم‌گروهی جامع در سال 1391 در شهر قم انجام شد. شرکت‌کنندگان120بیمار دیابتی بودند که 58 نفر از آن‌ها موافقت کردند که به طور تصادفی در دو گروه قرار بگیرند و 62 بیمار طبق ترجیح خود در دو گروه دیگر قرار گرفتند. برای گروه درمان در گروه‌های تصادفی‌شده و ترجیحی، یک عدد قرص ویتامین D 50000 واحدی خوراکی هر هفته یک عدد برای مدت 3 ماه استفاده شد. در گروه شاهد یک عدد قرص دارونمای ویتامین D، مشابه روش توضیح داده‌شده در بالا، داده شد. در گروه ترجیحی، بیماران نه ویتامین دریافت کردند و نه دارونما. وجود مقاومت به انسولین به صورت HOMA-IR (Homeostatic model assessment: insulin resistance) بیشتر از 87/3 تعریف شد.یافته‌ها: پس از کنترل متغیر‌های جنس، سن، شاخص توده‌ی بدنی، دور کمر، مدت ابتلا به دیابت، بیماری قلبی و نمایه‌ی HOMA-IR، نتایج این مطالعه نشان داد که ویتامین D در گروه تصادفی‌شده به طور معنی‌داری باعث کاهش نمایه‌ی HOMA-IR گردید، اما در گروه ترجیحی (هم‌گروهی) این کاهش از نظر آماری معنی‌دار نبود.نتیجه‌گیری: ویتامین D می‌تواند بر کاهش سطح قند خون ناشتا و مقاومت انسولین در گروه تصادفی‌شده مؤثر باشد اما در گروه ترجیحی قادر به این کاهش نیست.

کلیدواژه‌ها

عنوان مقاله [English]

Impact of Vitamin D on Insulin Resistance in Patients with Type ΙΙ Diabetes: A Comprehensive Cohort Design

نویسندگان [English]

  • Mostafa Vahedian 1
  • Mohammad Reza Maracy 2
  • Mahmood Parham 3
1 MSc Student, Department of Epidemiology and Biostatistics, School of Health AND Student Research Committee, Isfahan University of Medical Sciences, Isfahan, Iran
2 Associate Professor, Department of Epidemiology and Biostatistics, School of Health, Isfahan University of Medical Sciences, Isfahan, Iran
3 Assistant Professor, Clinical Development Research Center, Qom University of Medical Sciences, Qom, Iran
چکیده [English]

Background: Some observational studies show that the consumption of vitamin D is one of the preventive methods which may potentially be useful in the reduction of diabetes type ΙΙ development, insulin resistance, impaired glucose tolerance, and metabolic syndrome. The purpose of this study was to evaluate the effect of vitamin D on insulin resistance in patients with type II diabetes.Methods: This study was conducted as a comprehensive cohort design in Qom, Iran, in 2012. The participants were 120 patients with type II diabetes of whom, 58 agreed to be randomized into two groups and 62 patients were allocated to their preferences. For randomized treatment group, a pill of vitamin D which contained 50000 units was used weekly and orally for duration of 3 months. In the control group, the placebo pill of vitamin D was prescribed by the same method. In the preferential group, patients received neither vitamin D nor placebo. The value of insulin resistance was defined as a score greater than 3.87 in HOMA-IR (Homeostatic model assessment -estimated insulin resistance) index.Findings: Vitamin D could significantly decrease the HOMA-IR index in the randomized group after controlling for the variables of sex, age, body mass index (BMI), waist, duration of diabetes, heart disease, and HOMA-IR index at the beginning of the study. The reduction was not statistically significant in the preferential group.Conclusion: Vitamin D can affect the reduction of fasting blood sugar (FBS) and insulin resistance in the randomized group but in the preferential group it cannot.

کلیدواژه‌ها [English]

  • Vitamin D
  • Insulin Resistance
  • Type ΙΙ diabetes
  • Comprehensive cohort design

مراجع

  1. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004; 27(5): 1047-53.
  2. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2010; 33(Suppl 1): S62-S69.
  3. Arslanian SA. Type 2 diabetes mellitus in children: pathophysiology and risk factors. J Pediatr Endocrinol Metab 2000; 13(Suppl 6): 1385-94.
  4. Eliades M, Pittas AG. Vitamin D and Type 2 Diabetes. Clinical Reviews in Bone and Mineral Metabolism 2009; 7(2): 185-98.
  5. Morgan CL, Currie CJ, Peters JR. Relationship between diabetes and mortality: a population study using record linkage. Diabetes Care 2000; 23(8): 1103-7.
  6. Laakso M. Insulin resistance and its impact on the approach to therapy of type 2 diabetes. Int J Clin Pract Suppl 2001; (121): 8-12.
  7. Hoehn KL, Salmon AB, Hohnen-Behrens C, Turner N, Hoy AJ, Maghzal GJ, et al. Insulin resistance is a cellular antioxidant defense mechanism. Proc Natl Acad Sci U S A 2009; 106(42): 17787-92.
  8. Goldberg RB. Cytokine and cytokine-like inflammation markers, endothelial dysfunction, and imbalanced coagulation in development of diabetes and its complications. J Clin Endocrinol Metab 2009; 94(9): 3171-82.
  9. Souberbielle JC, Cormier C, Kindermans C, Gao P, Cantor T, Forette F, et al. Vitamin D status and redefining serum parathyroid hormone reference range in the elderly. J Clin Endocrinol Metab 2001; 86(7): 3086-90.
  10. Heshmat R, Mohammad K, Majdzadeh SR, Forouzanfar MH, Bahrami A, Ranjbar Omrani GH, et al. Vitamin D deficiency in Iran: A multi-center study among different urban areas. Iran J Public Health 2008; 37(Suppl): 72-8.
  11. Baz-Hecht M, Goldfine AB. The impact of vitamin D deficiency on diabetes and cardiovascular risk. Curr Opin Endocrinol Diabetes Obes 2010; 17(2): 113-9.
  12. Borissova AM, Tankova T, Kirilov G, Dakovska L, Kovacheva R. The effect of vitamin D3 on insulin secretion and peripheral insulin sensitivity in type 2 diabetic patients. Int J Clin Pract 2003; 57(4): 258-61.
  13. Forouhi NG, Luan J, Cooper A, Boucher BJ, Wareham NJ. Baseline serum 25-hydroxy vitamin d is predictive of future glycemic status and insulin resistance: the Medical Research Council Ely Prospective Study 1990-2000. Diabetes 2008; 57(10): 2619-25.
  14. Scragg R, Sowers M, Bell C. Serum 25-hydroxyvitamin D, diabetes, and ethnicity in the Third National Health and Nutrition Examination Survey. Diabetes Care 2004; 27(12): 2813-8.
  15. Chiu KC, Chu A, Go VL, Saad MF. Hypovitaminosis D is associated with insulin resistance and beta cell dysfunction. Am J Clin Nutr 2004; 79(5): 820-5.
  16. Zeitz U, Weber K, Soegiarto DW, Wolf E, Balling R, Erben RG. Impaired insulin secretory capacity in mice lacking a functional vitamin D receptor. FASEB J 2003; 17(3): 509-11.
  17. Melamed ML, Michos ED, Post W, Astor B. 25-hydroxyvitamin D levels and the risk of mortality in the general population. Arch Intern Med 2008; 168(15): 1629-37.
  18. Michos ED, Reis JP, Melamed ML. Vitamin D status and cardiovascular health: A 2009 update. The Open Clinical Chemistry Journal 2010; 3: 51-9.
  19. Ford ES, Ajani UA, McGuire LC, Liu S. Concentrations of serum vitamin D and the metabolic syndrome among U.S. adults. Diabetes Care 2005; 28(5): 1228-30.
  20. Hotamisligil GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM. Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J Clin Invest 1995; 95(5): 2409-15.
  21. Riachy R, Vandewalle B, Moerman E, Belaich S, Lukowiak B, Gmyr V, et al. 1,25-Dihydroxyvitamin D3 protects human pancreatic islets against cytokine-induced apoptosis via down-regulation of the Fas receptor. Apoptosis 2006; 11(2): 151-9.
  22. Schleithoff SS, Zittermann A, Tenderich G, Berthold HK, Stehle P, Koerfer R. Vitamin D supplementation improves cytokine profiles in patients with congestive heart failure: a double-blind, randomized, placebo-controlled trial. Am J Clin Nutr 2006; 83(4): 754-9.
  23. Inomata S, Kadowaki S, Yamatani T, Fukase M, Fujita T. Effect of 1 alpha (OH)-vitamin D3 on insulin secretion in diabetes mellitus. Bone Miner 1986; 1(3): 187-92.
  24. Jorde R, Figenschau Y. Supplementation with cholecalciferol does not improve glycaemic control in diabetic subjects with normal serum 25-hydroxyvitamin D levels. Eur J Nutr 2009; 48(6): 349-54.
  25. Tai K, Need AG, Horowitz M, Chapman IM. Glucose tolerance and vitamin D: effects of treating vitamin D deficiency. Nutrition 2008; 24(10): 950-6.
  26. Hashemipour S, Larijani B, Adibi H, Javadi E, Sedaghat M, Pajouhi M, et al. Vitamin D deficiency and causative factors in the population of Tehran. BMC Public Health 2004; 4: 38.
  27. Bonakdaran S, Varasteh A, Khaajeh-Dalouie M. Serum 25 hydroxy vitamin D3 and laboratory risk markers of cardiovascular diseases in type 2 diabetic patients. Iran J Endocrinol Metab 2010; 11(5): 504-9.
  28. Schmoor C, Olschewski M, Schumacher M. Randomized and non-randomized patients in clinical trials: experiences with comprehensive cohort studies. Stat Med 1996; 15(3): 263-71.
  29. Muche R, Imhof A. The Comprehensive Cohort Design as alternative to the randomized controlled trial in rehabilitation research: advantages, disadvantages, and implementation in the SARAH study. Rehabilitation (Stuttg) 2003; 42(6): 343-9. [In German].
  30. Kearney RS, Achten J, Parsons NR, Costa ML. The comprehensive cohort model in a pilot trial in orthopaedic trauma. BMC Med Res Methodol 2011; 11: 39.
  31. Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care 2004; 27(6): 1487-95.
  32. Esteghamati A, Ashraf H, Khalilzadeh O, Zandieh A, Nakhjavani M, Rashidi A, et al. Optimal cut-off of homeostasis model assessment of insulin resistance (HOMA-IR) for the diagnosis of metabolic syndrome: third national surveillance of risk factors of non-communicable diseases in Iran (SuRFNCD-2007). Nutr Metab (Lond) 2010; 7: 26.
  33. Holick MF. High prevalence of vitamin D inadequacy and implications for health. Mayo Clin Proc 2006; 81(3): 353-73.
  34. Dawson-Hughes B, Heaney RP, Holick MF, Lips P, Meunier PJ, Vieth R. Estimates of optimal vitamin D status. Osteoporos Int 2005; 16(7): 713-6.
  35. Pittas AG, Harris SS, Stark PC, Dawson-Hughes B. The effects of calcium and vitamin D supplementation on blood glucose and markers of inflammation in nondiabetic adults. Diabetes Care 2007; 30(4): 980-6.
  36. von Hurst PR, Stonehouse W, Coad J. Vitamin D supplementation reduces insulin resistance in South Asian women living in New Zealand who are insulin resistant and vitamin D deficient - a randomised, placebo-controlled trial. Br J Nutr 2010; 103(4): 549-55.
  37. Witham MD, Dove FJ, Dryburgh M, Sugden JA, Morris AD, Struthers AD. The effect of different doses of vitamin D(3) on markers of vascular health in patients with type 2 diabetes: a randomised controlled trial. Diabetologia 2010; 53(10): 2112-9.
  38. Chonchol M, Scragg R. 25-Hydroxyvitamin D, insulin resistance, and kidney function in the Third National Health and Nutrition Examination Survey. Kidney Int 2007; 71(2): 134-9.
  39. Lu L, Yu Z, Pan A, Hu FB, Franco OH, Li H, et al. Plasma 25-hydroxyvitamin D concentration and metabolic syndrome among middle-aged and elderly Chinese individuals. Diabetes Care 2009; 32(7): 1278-83.
  40. Gannage-Yared MH, Chedid R, Khalife S, Azzi E, Zoghbi F, Halaby G. Vitamin D in relation to metabolic risk factors, insulin sensitivity and adiponectin in a young Middle-Eastern population. Eur J Endocrinol 2009; 160(6): 965-71.
  41. McGill AT, Stewart JM, Lithander FE, Strik CM, Poppitt SD. Relationships of low serum vitamin D3 with anthropometry and markers of the metabolic syndrome and diabetes in overweight and obesity. Nutr J 2008; 7: 4.
مجله دانشکده پزشکی اصفهان
دوره 31، شماره 239 - شماره پیاپی 239
مرداد و شهریور 1392
صفحه 777-791

فایل ها

سابقه مقاله

  • تاریخ دریافت: 19 دی 1391
  • تاریخ بازنگری: 11 آبان 1403
  • تاریخ پذیرش: 17 فروردین 1401

هم رسانی

ارجاع به این مقاله

آمار